Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that Tim Mayleben has been appointed Chief Executive Officer, effective immediately. Eric Edwards, M.D., Ph.D., Phlow’s co-founder and former CEO, has transitioned to the role of Chairman Emeritus and Strategic Advisor to the CEO and Board of Directors.
The leadership transition reflects a planned evolution designed to position Phlow for its next phase of growth as it advances its mission to strengthen domestic pharmaceutical manufacturing and modernize how medicines are made in America.
Dr. Edwards co-founded Phlow with a singular mission, to help brilliant minds bring medicines to life through advanced development and manufacturing in America. Under his leadership, the company secured foundational government partnerships, built advanced manufacturing capabilities in Richmond, Virginia, and established itself as a new model for domestic pharmaceutical production. As part of a planned leadership evolution developed in close partnership with the Board of Directors, Dr. Edwards led the search for and selection of his successor to ensure the company’s next chapter is led with the same rigor and purpose that defined its first.
“Phlow is entering a critical phase where disciplined execution and operational scale are paramount. Tim brings the experience and leadership track record this moment requires,” said Edwards, “This transition allows me to remain deeply engaged in advancing Phlow’s mission and national partnerships, while Tim drives the day-to-day execution that will take Phlow to its next level.”
Mayleben has served on Phlow’s Business Advisory Board since 2023, transitioning to the corporate Board of Directors in 2025 and now serving as Board Chairman, giving him a deep and direct understanding of Phlow’s programs, operations, and the mission-critical partnerships that define the company’s work.
Mayleben brings more than 25 years of executive leadership in the life sciences and pharmaceutical industries, with a track record of building and scaling organizations from early-stage development through regulatory approval, commercial launch, and sustained growth. His experience spans organizational leadership, capital strategy, and operational scale across the biotech and pharmaceutical sectors, including service as President and CEO of Esperion Therapeutics.
In his role as Chairman Emeritus and Strategic Advisor, Dr. Edwards will continue to serve on Phlow’s Board of Directors and provide strategic counsel on national partnerships and long-term strategic and innovation initiatives. He will also serve as Chief Executive Officer of MedPhlow, a Phlow subsidiary focused on developing and commercializing novel essential medicine delivery solutions.
Read more here.